Comments on: Nasus Pharma Announces Ground-Breaking Five Years Stability of its FMXIN002 Nasal Epinephrine Powder for Severe Allergy and Anaphylaxis

Comments on: Nasus Pharma Announces Ground-Breaking Five Years Stability of its FMXIN002 Nasal Epinephrine Powder for Severe Allergy and Anaphylaxis https://www.nasuspharma.com/nasus-pharma-announces-positive-clinical-results-of-recent-phase-2-study-with-fmxin002-intranasal-epinephrine-copy/?utm_source=rss&utm_medium=rss&utm_campaign=nasus-pharma-announces-positive-clinical-results-of-recent-phase-2-study-with-fmxin002-intranasal-epinephrine-copy New frontier in Intranasal drug delivery Wed, 07 Aug 2024 09:00:45 +0000 hourly 1 https://wordpress.org/?v=6.6.2